Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection

Journal of Immunology

Volumn 186, Issue 2, 2011, Pages 1151-1161

  Gabryszewski, Stanislaw J ^a   Bachar, Ofir ^a   Dyer, Kimberly D ^a   Percopo, Caroline M ^a   Killoran, Kristin E ^a,c   Domachowske, Joseph B ^b   Rosenberg, Helene F ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; GENE DELETION; GRANULOCYTE; HISTOPATHOLOGY; INNATE IMMUNITY; INOCULATION; LACTOBACILLUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LISTERIA INNOCUA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PNEUMOVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT MUCOSA; SURVIVAL; VIRUS IMMUNITY; VIRUS SURVIVAL; VIRUS VIRULENCE; WILD TYPE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, VIRAL; CYTOKINES; INFLAMMATION MEDIATORS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MURINE PNEUMONIA VIRUS; PNEUMOVIRUS INFECTIONS; RESPIRATORY MUCOSA; VIRUS REPLICATION;

EID: 79251558125     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001751     Document Type: Article

References (59)

1. Tregoning, J. S., and J. Schwarze. 2010. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin. Microbiol. Rev. 23: 74-98.
2. Falsey, A. R., and E. E. Walsh. 2005. Respiratory syncytial virus infection in elderly adults. Drugs Aging 22: 577-587.
3. Welliver, R. C. 2003. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J. Pediatr. 143(5, Suppl.)S112-S117.
4. Hall, C. B., G. A. Weinberg, M. K. Iwane, A. K. Blumkin, K. M. Edwards, M. A. Staat, P. Auinger, M. R. Griffin, K. A. Poehling, D. Erdman, et al. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360: 588-598.
5. Olszewska, W., and P. Openshaw. 2009. Emerging drugs for respiratory syncytial virus infection. Expert Opin. Emerg. Drugs 14: 207-217.
6. Rosenberg, H. F., and J. B. Domachowske. 2008. Pneumonia virus of mice: severe respiratory infection in a natural host. Immunol. Lett. 118: 6-12.
7. Easton, A. J., J. B. Domachowske, and H. F. Rosenberg. 2006. Pneumonia virus of mice. In Perspectives in Medical Virology, Vol. 12. P. Cane, ed. Elsevier, Amsterdam, p. 299-319.
8. Anh, D. B., P. Faisca, and D. J. Desmecht. 2006. Differential resistance/susceptibility patterns to pneumovirus infection among inbred mouse strains. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L426-L435.
9. McNamara, P. S., B. F. Flanagan, C. A. Hart, and R. L. Smyth. 2005. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J. Infect. Dis. 191: 1225-1232.
10. Johnson, J. E., R. A. Gonzales, S. J. Olson, P. F. Wright, and B. S. Graham. 2007. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod. Pathol. 20: 108-119.
11. Bataki, E. L., G. S. Evans, and M. L. Everard. 2005. Respiratory syncytial virus and neutrophil activation. Clin. Exp. Immunol. 140: 470-477.
12. Bonville, C. A., A. J. Easton, H. F. Rosenberg, and J. B. Domachowske. 2003. Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents. J. Virol. 77: 1237-1244.
13. Bonville, C. A., V. K. Lau, J. M. DeLeon, J. L. Gao, A. J. Easton, H. F. Rosenberg, and J. B. Domachowske. 2004. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J. Virol. 78: 7984-7989.
14. Ventre, K., and A. Randolph. 2004. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst. Rev. (4):):CD000181.
15. Rosenberg, H. F., C. A. Bonville, A. J. Easton, and J. B. Domachowske. 2005. The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention. Pharmacol. Ther. 105: 1-6.
16. Borchers, A. T., C. Selmi, F. J. Meyers, C. L. Keen, and M. E. Gershwin. 2009. Probiotics and immunity. J. Gastroenterol. 44: 26-46.
17. Vaarala, O. 2003. Immunological effects of probiotics with special reference to lactobacilli. Clin. Exp. Allergy 33: 1634-1640.
18. Shanahan, F. 2005. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases, I: Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G417-G421.
19. Boirivant, M., and W. Strober. 2007. The mechanism of action of probiotics. Curr. Opin. Gastroenterol. 23: 679-692.
20. Lomax, A. R., and P. C. Calder. 2009. Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans. Curr. Pharm. Des. 15: 1428-1518.
21. Maeda, N., R. Nakamura, Y. Hirose, S. Murosaki, Y. Yamamoto, T. Kase, and Y. Yoshikai. 2009. Oral administration of heat-killed Lactobacillus plantarum L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. Int. Immunopharmacol. 9: 1122-1125.
22. Vouloumanou, E. K., G. C. Makris, D. E. Karageorgopoulos, and M. E. Falagas. 2009. Probiotics for the prevention of respiratory tract infections: a systematic review. Int. J. Antimicrob. Agents 34: 197.e1- 197.e10.
23. Hols, P., P. Slos, P. Dutot, J. Reymund, P. Chabot, B. Delplace, J. Delcour, and A. Mercenier. 1997. Efficient secretion of the model antigen M6-gp41E in Lactobacillus plantarum NCIMB 8826. Microbiology 143: 2733-2741.
24. Kandler, O., K. Stetter, and R. Köhl. 1980. Lactobacillus reuteri sp. nov., a new species of heterofermentative lactobacilli. Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. 1: 264-269.
25. Mondofacto Medical Dictionary Search Online. Available at: http://www.mondofacto.com/dictionary. Accessed: September 15, 2010.
26. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
27. Domachowske, J. B., C. A. Bonville, J. L. Gao, P. M. Murphy, A. J. Easton, and H. F. Rosenberg. 2000. The chemokine macrophage-inflammatory protein-1α and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J. Immunol. 165: 2677-2682.
28. Percopo, C. M., Z. Qiu, S. Phipps, P. S. Foster, J. B. Domachowske, and H. F. Rosenberg. 2009. Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice. J. Immunol. 183: 604-612.
29. Garvy, B. A., and M. H. Qureshi. 2000. Delayed inflammatory response to Pneumocystis carinii infection in neonatal mice is due to an inadequate lung environment. J. Immunol. 165: 6480-6486.
30. Bonville, C. A., N. J. Bennett, M. Koehnlein, D. M. Haines, J. A. Ellis, A. M. DelVecchio, H. F. Rosenberg, and J. B. Domachowske. 2006. Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis. Virology 349: 87-95.
31. Bienenstock, J., and M. R. McDermott. 2005. Bronchus- and nasal-associated lymphoid tissues. Immunol. Rev. 206: 22-31.
32. Foo, S. Y., and S. Phipps. 2010. Regulation of inducible BALT formation and contribution to immunity and pathology. Mucosal Immunol. 3: 537-544.
33. Welliver, R. C., Sr. 2008. The immune response to respiratory syncytial virus infection: friend or foe? Clin. Rev. Allergy Immunol. 34: 163-173.
34. Neote, K., D. DiGregorio, J. Y. Mak, R. Horuk, and T. J. Schall. 1993. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 72: 415-425.
35. Mengheri, E. 2008. Health, probiotics, and inflammation. J. Clin. Gastroenterol. 42(Suppl 3 Pt 2): S177-S178.
36. Torii, A., S. Torii, S. Fujiwara, H. Tanaka, N. Inagaki, and H. Nagai. 2007. Lactobacillus acidophilus strain L-92 regulates the production of Th1 cytokine as well as Th2 cytokines. Allergol. Int. 56: 293-301.
37. Kitazawa, H., K. Matsumura, T. Itoh, and T. Yamaguchi. 1992. Interferon induction in murine peritoneal macrophage by stimulation with Lactobacillus acidophilus. Microbiol. Immunol. 36: 311-315.
38. Kopp, M. V., M. Goldstein, A. Dietschek, J. Sofke, A. Heinzmann, and R. Urbanek. 2008. Lactobacillus GG has in vitro effects on enhanced interleukin-10 and interferon-γ release of mononuclear cells but no in vivo effects in supplemented mothers and their neonates. Clin. Exp. Allergy 38: 602-610.
39. Lakatos, P. L., S. Fischer, L. Lakatos, I. Gal, and J. Papp. 2006. Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "Toll"? World J. Gastroenterol. 12: 1829-1841.
40. Hori, T., J. Kiyoshima, K. Shida, and H. Yasui. 2001. Effect of intranasal administration of Lactobacillus casei Shirota on influenza virus infection of upper respiratory tract in mice. Clin. Diagn. Lab. Immunol. 8: 593-597.
41. Harata, G., F. He, N. Hiruta, M. Kawase, A. Kubota, M. Hiramatsu, and H. Yausi. 2010. Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses. Lett. Appl. Microbiol. 50: 597-602.
42. Izumo, T., T. Maekawa, M. Ida, A. Noguchi, Y. Kitagawa, H. Shibata, H. Yasui, and Y. Kiso. 2010. Effect of intranasal administration of Lactobacillus pentosus S-PT84 on influenza virus infection in mice. Int. Immunopharmacol. 10: 1101-1106.
43. Rautava, S., M. Kalliomäki, and E. Isolauri. 2005. New therapeutic strategy for combating the increasing burden of allergic disease: Probiotics-A Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. J. Allergy Clin. Immunol. 116: 31-37.
44. Zeuthen, L. H., L. N. Fink, and H. Frøkiaer. 2008. Toll-like receptor 2 and nucleotide-binding oligomerization domain-2 play divergent roles in the recognition of gut-derived lactobacilli and bifidobacteria in dendritic cells. Immunology 124: 489-502.
45. Mohamadzadeh, M., and T. R. Klaenhammer. 2008. Specific Lactobacillus species differentially activate Toll-like receptors and downstream signals in dendritic cells. Expert Rev. Vaccines 7: 1155-1164.
46. Didierlaurent, A., J. Goulding, S. Patel, R. Snelgrove, L. Low, M. Bebien, T. Lawrence, L. S. van Rijt, B. N. Lambrecht, J.-C. Sirard, and T. Hussell. 2008. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J. Exp. Med. 205: 323-329.
47. Hisbergues, M., M. Magi, P. Rigaux, J. Steuve, L. Garcia, D. Goudercourt, B. Pot, J. Pestel, and A. Jacquet. 2007. In vivo and in vitro immunomodulation of Der p 1 allergen-specific response by Lactobacillus plantarum bacteria. Clin. Exp. Allergy 37: 1286-1295.
48. Ichikawa, S., R. Fujii, D. Fujiwara, Y. Komiyama, T. Kaisho, M. Sakaguchi, and Y. Konishi. 2007. MyD88 but not TLR2, 4 or 9 is essential for IL-12 induction by lactic acid bacteria. Biosci. Biotechnol. Biochem. 71: 3026-3032.
49. Chung, Y. W., J. H. Choi, T. Y. Oh, C. S. Eun, and D. S. Han. 2008. Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice. Clin. Exp. Immunol. 151: 182-189.
50. Bhoj, V. G., Q. Sun, E. J. Bhoj, C. Somers, X. Chen, J. P. Torres, A. Mejias, A. M. Gomez, H. Jafri, O. Ramilo, and Z. J. Chen. 2008. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA 105: 14046-14051.
51. Dyer, K.D., C. M. Percopo, E. R. Fischer, S. J. Gabryszewski, and H. F. Rosenberg. 2009. Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood 114: 2649-2656.
52. Klein Klouwenberg, P., L. Tan, W. Werkman, G. M. van Bleek, and F. E. J. Coenjaerts. 2009. The role of Toll-like receptors in regulating the immune response against respiratory syncytial virus. Crit. Rev. Immunol. 29: 531-550.
53. van der Sluijs, K. F., L. van Elden, M. Nijhuis, R. Schuurman, S. Florquin, H. M. Jansen, R. Lutter, and T. van der Poll. 2003. Toll-like receptor 4 is not involved in host defense against respiratory tract infection with Sendai virus. Immunol. Lett. 89: 201-206.
54. Faisca, P., D. B. Tran Anh, A. Thomas, and D. Desmecht. 2006. Suppression of pattern-recognition receptor TLR4 sensing does not alter lung responses to pneumovirus infection. Microbes Infect. 8: 621-627.
55. Garofalo, R. P., J. Patti, K. A. Hintz, V. Hill, P. L. Ogra, and R. C. Welliver. 2001. Macrophage inflammatory protein-1a (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J. Infect. Dis. 184: 393-399.
56. Culley, F. J., A. M. Pennycook, J. S. Tregoning, T. Hussell, and P. J. Openshaw. 2006. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J. Virol. 80: 4521-4527.
57. + T cell efficacy. Eur. J. Immunol. 38: 2168-2179.
58. Puthothu, B., S. Bierbaum, M. V. Kopp, J. Forster, J. Heinze, M. Weckmann, M. Krueger, and A. Heinzmann. 2009. Association of TNF-α with severe respiratory syncytial virus infection and bronchial asthma.Pediatr. Allergy Immunol. 20: 157-163.
59. McNamara, P. S., B. F. Flanagan, A. M. Selby, C. A. Hart, and R. L. Smyth. 2004. Pro- and anti-inflammatory responses in respiratory syncytial virus bronchiolitis. Eur. Respir. J. 23: 106-112.